These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 27897303)

  • 41. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
    Deleu D; Hanssens Y; Northway MG
    Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus.
    Spottke EA; Volkmann J; Lorenz D; Krack P; Smala AM; Sturm V; Gerstner A; Berger K; Hellwig D; Deuschl G; Freund HJ; Oertel WH; Dodel RC
    J Neurol; 2002 Jun; 249(6):759-66. PubMed ID: 12111311
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Carbidopa levodopa enteral suspension.
    Seeberger LC; Hauser RA
    Expert Opin Pharmacother; 2015; 16(18):2807-17. PubMed ID: 26595228
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review.
    Wirdefeldt K; Odin P; Nyholm D
    CNS Drugs; 2016 May; 30(5):381-404. PubMed ID: 27138916
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of subcutaneous infusion of apomorphine in Parkinson's disease.
    Wenzel K; Homann CN; Fabbrini G; Colosimo C
    Expert Rev Neurother; 2014 Jul; 14(7):833-43. PubMed ID: 24917215
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes.
    Antonini A; Yegin A; Preda C; Bergmann L; Poewe W;
    Parkinsonism Relat Disord; 2015 Mar; 21(3):231-5. PubMed ID: 25585993
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease.
    Clarke CE; Worth P; Grosset D; Stewart D
    Parkinsonism Relat Disord; 2009 Dec; 15(10):728-41. PubMed ID: 19805000
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Practical approaches to commencing device-assisted therapies for Parkinson disease in Australia.
    Williams DR; Evans AH; Fung VSC; Hayes M; Iansek R; Kimber T; O'Sullivan JD; Sue CM
    Intern Med J; 2017 Oct; 47(10):1107-1113. PubMed ID: 28195385
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management.
    Antonini A; Tolosa E
    Expert Rev Neurother; 2009 Jun; 9(6):859-67. PubMed ID: 19496689
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-utility analysis of Parkinson's disease.
    Shan DE; Wu HC; Chan LY; Liu KD
    Acta Neurol Taiwan; 2011 Mar; 20(1):65-72. PubMed ID: 21249581
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness analysis of dopamine agonists in the treatment of Parkinson's disease in Japan.
    Shimbo T; Hira K; Takemura M; Fukui T
    Pharmacoeconomics; 2001; 19(8):875-86. PubMed ID: 11596839
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus.
    De Gaspari D; Siri C; Landi A; Cilia R; Bonetti A; Natuzzi F; Morgante L; Mariani CB; Sganzerla E; Pezzoli G; Antonini A
    J Neurol Neurosurg Psychiatry; 2006 Apr; 77(4):450-3. PubMed ID: 16543520
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Duodenal Levodopa Infusion for Long-Term Deep Brain Stimulation-Refractory Symptoms in Advanced Parkinson Disease.
    Regidor I; Benita V; Del Álamo de Pedro M; Ley L; Martinez Castrillo JC
    Clin Neuropharmacol; 2017; 40(3):103-107. PubMed ID: 28452905
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Costs of drug treatment in Parkinson's disease.
    Dodel RC; Eggert KM; Singer MS; Eichhorn TE; Pogarell O; Oertel WH
    Mov Disord; 1998 Mar; 13(2):249-54. PubMed ID: 9539337
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness of pergolide compared to bromocriptine in the treatment of Parkinson's disease: a decision-analytic model.
    Davey P; Rajan N; Lees M; Aristides M
    Value Health; 2001; 4(4):308-15. PubMed ID: 11705298
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease.
    Fraix V; Houeto JL; Lagrange C; Le Pen C; Krystkowiak P; Guehl D; Ardouin C; Welter ML; Maurel F; Defebvre L; Rougier A; Benabid AL; Mesnage V; Ligier M; Blond S; Burbaud P; Bioulac B; Destée A; Cornu P; Pollak P;
    J Neurol Neurosurg Psychiatry; 2006 Apr; 77(4):443-9. PubMed ID: 16543519
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Duodenal levodopa infusion for advanced Parkinson's disease in Finland 2006-2010].
    Pursiainen V; Pekkonen E
    Duodecim; 2012; 128(16):1707-15. PubMed ID: 23025155
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Subthalamic Nucleus Deep Brain Stimulation May Reduce Medication Costs in Early Stage Parkinson's Disease.
    Hacker ML; Currie AD; Molinari AL; Turchan M; Millan SM; Heusinkveld LE; Roach J; Konrad PE; Davis TL; Neimat JS; Phibbs FT; Hedera P; Byrne DW; Charles D
    J Parkinsons Dis; 2016; 6(1):125-31. PubMed ID: 26967937
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The need for non-oral therapy in Parkinson's disease; a potential role for apomorphine.
    van Laar T; Borgemeester R
    Parkinsonism Relat Disord; 2016 Dec; 33 Suppl 1():S22-S27. PubMed ID: 27998652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.